Inflammatory plasma markers and pancreatic cancer risk: A prospective study of five U.S. cohorts

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 5, 2013, Pages 855-861

  Bao, Ying ^a   Giovannucci, Edward L ^a,b,e   Kraft, Peter ^d,e   Qian, Zhi Rong ^h   Wu, Chen ^e   Ogino, Shuji ^c,e,h   Gaziano, J Michael ^b,m   Stampfer, Meir J ^a,b,e   Ma, Jing ^a,e   Buring, Julie E ^b,d,e   Sesso, Howard D ^b,d,e   Lee, I Min ^b,d,e   Rifai, Nader ^g   Pollak, Michael N ⁱ   Jiao, Li ^j   Lessin, Lawrence ^l,n   Cochrane, Barbara B ^k   Manson, Joann E ^a,b,e,f   Fuchs, Charles S ^a,h   Wolpin, Brian M ^a,h  

^a CHANNING LABORATORY   (United States)

^b Department of Medicine ^*  (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Health Services and Epidemiology   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l WEST VIRGINIA UNIVERSITY   (United States)

^m VA BOSTON HEALTHCARE SYSTEM   (United States)

ⁿ MEDSTAR RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CHRONIC INFLAMMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS CANCER; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84877937625     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1458     Document Type: Article

References (46)

1. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology. 2002;16:217-26.
2. Kundu JK, Surh YJ. Inflammation: Gearing the journey to cancer. Mutat Res 2008;659:15-30.
3. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-6.
4. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
5. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921-9.
6. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-69.
7. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004;239:763-9.
8. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 2008;149: 319-028.
9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
10. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113: 2128-34.
11. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-7.
12. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
13. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4.
14. Nathan C. Epidemic inflammation: Pondering obesity. Mol Med 2008;14:485-92.
15. Naugler WE, Karin M. The wolf in sheep's clothing: The role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14:109-19.
16. Masui T, Hosotani R, Doi R, Miyamoto Y, Tsuji S, Nakajima S, et al. Expression of IL-6 receptor in pancreatic cancer: Involvement in VEGF induction. Anticancer Res 2002;22:4093-100.
17. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA. Cytokine regulation of constitutive production of interleukin-8 and-6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002; 21:881-6.
18. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005;5:514-29.
19. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
20. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: The Rotterdam Study. J Clin Oncol 2006;24:5216-22.
21. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: A prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4.
22. Barber MD, Fearon KC, Ross JA. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond) 1999;96:83-7.
23. Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: Relationship to acute phase response and survival. Oncol Rep 2009;21:1091-5.
24. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010;24:256-61.
25. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 2009;56:56-62.
26. Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, et al. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev 2011;20:359-69.
27. Grote VA, Kaaks R, Nieters A, Tjonneland A, Halkjaer J, Overvad K, et al. Inflammation marker and risk of pancreatic cancer: A nested casecontrol study within the EPIC cohort. Br J Cancer 2012;106:1866-74.
28. Giovannucci E, Ascherio A, RimmEB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34.
29. Colditz GA, Hankinson SE. The Nurses' Health Study: Lifestyle and health among women. Nat Rev Cancer 2005;5:388-96.
30. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: Baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13(9 Suppl):S107-21.
31. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005; 294:47-55.
32. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
33. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005;97:1688-94.
34. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302.
35. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13(9 Suppl):S5-17.
36. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
37. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 1999;59:1225-30.
38. Pai JK, Curhan GC, Cannuscio CC, Rifai N, Ridker PM, Rimm EB. Stability of novel plasma markers associated with cardiovascular disease: Processing within 36 hours of specimen collection. Clin Chem 2002;48:1781-4.
39. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study. Circulation 2007;116:1234-41.
40. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53: 693-700.
41. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.
42. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the national death index and equifax nationwide death search. Am J Epidemiol 1994;140:1016-9.
43. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107: 499-511.
44. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989 May;8:551-61.
45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
46. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 2003; 108:155-60.